BiotechTube
Jaan Biotherapeutics

Jaan Biotherapeutics

Cambridge, United States· Est.
jaanbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Jaan Biotherapeutics is pioneering a regenerative medicine approach for cardiovascular diseases by targeting a conserved microRNA program to stimulate heart muscle repair. The company's lead programs focus on reducing infarct size in ischemic heart disease (IHD) and treating hypertrophic cardiomyopathy (HCM), with plans to initiate clinical trials in 2027. It has secured significant intellectual property with over 30 patents and has been supported by multiple NIH Small Business grants. Jaan is currently seeking funding to advance its programs toward IND filings.

CardiovascularGenetic Disorders

Technology Platform

Proprietary platform manipulating a conserved network of four microRNAs to activate endogenous cardiac muscle regeneration. Utilizes both AAV-delivered gene therapy (for sustained inhibition) and synthetic oligonucleotides (for transient inhibition) as therapeutic modalities.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The global burden of cardiovascular disease, particularly ischemic heart disease and heart failure, represents a multi-billion dollar unmet need where current treatments manage symptoms but do not regenerate lost heart muscle.
Success would position Jaan as a pioneer in a transformative new therapeutic class.
The platform's potential applicability to other cardiac conditions, like DMD cardiomyopathy, offers pipeline expansion opportunities.

Risk Factors

High translational risk as the novel biology of reactivating cardiac regeneration in adult humans is unproven in the clinic.
The company is dependent on raising significant capital in a competitive funding environment to advance its preclinical programs.
As a first-in-class therapy, it faces regulatory uncertainty and a complex development path.

Competitive Landscape

Jaan operates in the competitive field of cardiac regeneration, facing rivals exploring cell therapies (e.g., stem cells), other gene therapy targets (e.g., Hippo pathway), RNA-based therapies, and small molecules. Its unique approach of targeting a specific quartet of miRNAs differentiates it, but it must demonstrate superior efficacy, safety, and delivery compared to other modalities.

More companies in Cell & Gene Therapy →More companies in United States →